LACTOLOGY FOUNDATION

Hyoscyamine (ATC A03BA03) is a tertiary amine belladonna alkaloid with anticholinergic effects; during lactation it is generally considered compatible at low, short-term doses but requires careful monitoring for maternal and infant anticholinergic adverse effects and possible reduction in milk production.medpedia.framar+2

Classification and pharmacology

Hyoscyamine is a naturally occurring tropane alkaloid from belladonna and related Solanaceae plants, belonging to ATC class A03BA03 “belladonna alkaloids, tertiary amines.”drugbank+2
It acts as a competitive antagonist at muscarinic acetylcholine receptors, producing anticholinergic effects such as reduced gastrointestinal motility, decreased glandular secretions, tachycardia and inhibition of smooth muscle spasm.glowm+3
Clinically, it is indicated for functional gastrointestinal disorders (irritable bowel-type complaints, spastic colitis), biliary and renal colic, and as an adjunct in peptic ulcer disease and acute rhinitis, as well as pre‑operative reduction of secretions and vagal reflexes.glowm+1

Toxicology and safety profile

Acute toxicity of hyoscyamine and its salts is high; safety data sheets classify hyoscyamine sulfate as “fatal if swallowed or inhaled” in concentrated form, reflecting its narrow therapeutic index.phyproof.phytolab
Typical anticholinergic adverse reactions include dry mouth, blurred vision, mydriasis, tachycardia, palpitations, urinary retention, constipation, decreased sweating, confusion, disorientation and short‑term memory loss, with particular vulnerability in elderly patients.accessdata.fda+2
Overdose presents with anticholinergic syndrome (hyperthermia, delirium, tachycardia, urinary retention, ileus), for which recommended measures include gastric lavage and parenteral physostigmine, along with supportive control of agitation, fever and respiratory function.dailymed.nlm.nih+1

Hyoscyamine has not been implicated in clinically apparent acute liver injury or significant elevations in liver enzymes, so hepatotoxicity is not a major concern.ncbi.nlm.nih
Cardiovascular risk relates mainly to tachyarrhythmias and exacerbation of existing cardiac disease, while central nervous system toxicity includes agitation, hallucinations and, at high doses, coma.dailymed.nlm.nih+2
Contraindications include hypersensitivity to the drug, as noted in the Bulgarian reference, and usual anticholinergic cautions: narrow‑angle glaucoma, urinary retention, obstructive uropathy, paralytic ileus, severe ulcerative colitis and myasthenia gravis.medpedia.framar+2

Lactation: pharmacokinetics and risk assessment

Available prescribing information indicates that hyoscyamine sulfate is excreted into human breast milk, but only trace amounts are typically detected; labels advise caution in nursing mothers.e-lactancia+1
Hyoscyamine has a relatively short half‑life (around 2–3.5 hours), with most of the absorbed dose excreted unchanged in urine within 12 hours, which limits sustained infant exposure from milk.droracle
Specialized lactation sources (E‑lactancia) classify hyoscyamine as “very low risk,” compatible with breastfeeding when minimal effective doses are used for short periods, while warning that anticholinergics may decrease milk production.e-lactation

Direct data on milk levels and infant serum concentrations are sparse, so risk assessment relies mainly on pharmacologic principles and extrapolation from related anticholinergics.doctronic+1
Anticholinergic action can theoretically reduce milk production and impair let‑down by inhibiting parasympathetic tone, especially with high doses or prolonged use.doctronic+1
In infants, potential adverse effects from exposure via breast milk include poor sucking and appetite, constipation, dry mouth and sedation or sleep pattern changes, though clinically significant effects appear uncommon at usual maternal doses.droracle+1

For gastrointestinal antispasmodics in breastfeeding, UK specialist pharmacy guidance considers hyoscine butylbromide, propantheline and peppermint oil as preferred options, with mebeverine and alverine also acceptable, suggesting that hyoscyamine should generally be reserved for cases where alternatives are unsuitable.sps+1
Clinical practice recommendations emphasize individualized risk–benefit analysis, short‑term use of the lowest effective dose, and close monitoring of both maternal lactation and infant symptoms.e-lactation+1
General lactation resources underline that most medications are compatible with breastfeeding and that breastfeeding should rarely be interrupted solely due to the need for pharmacotherapy, aligning with cautious but permissive use of low‑risk anticholinergics.kellymom+1

Clinical toxicology–lactology guidance

From a toxicological standpoint, the main breastfeeding‑related concerns are cumulative anticholinergic burden in the mother (risk of confusion, tachycardia, urinary retention) and subtle infant exposure leading to feeding or gastrointestinal changes.droracle+2
Hyoscyamine’s antispasmodic benefit in functional GI disorders must be weighed against its propensity to cause or worsen constipation, which is a documented adverse effect via reduced intestinal motility.drugbank+1
There is no evidence of hyoscyamine‑induced hepatotoxicity or specific lactation‑related organ toxicity, making neurologic, cardiovascular and GI side effects the primary domains to monitor.ncbi.nlm.nih+1

Practical risk‑minimization strategies during breastfeeding include:

·        Use the minimal effective dose, preferably intermittently and for short durations.doctronic+1

·        Time dosing immediately after breastfeeding or before the longest sleep interval to reduce peak milk concentrations during feeds.doctronic

·        Monitor the infant for decreased feeding, prolonged constipation, unusual sedation or irritability, and consult a healthcare professional if such signs appear.e-lactation+1

·        Consider alternative antispasmodics with more reassuring breastfeeding data (e.g. peppermint oil, mebeverine) whenever clinically appropriate.sps+1

In mothers with borderline milk supply or lactation difficulties, any anticholinergic may further compromise production, so hyoscyamine use should be especially conservative and ideally guided by a clinician familiar with lactation pharmacology.e-lactation+1
Because hyoscyamine crosses the placenta, pregnancy exposure should also be limited to clear indications, but this does not necessarily mandate cessation of breastfeeding postpartum when low‑dose therapy is required.dailymed.nlm.nih+1
Overall, for ATC A03BA03 drugs, hyoscyamine occupies a profile of “compatible with caution”: broadly acceptable in breastfeeding at low doses, but not a first‑line antispasmodic when safer alternatives exist.sps+2